New inhaled peptide aims to halt lung scarring in IPF patients
Disease control
Recruiting now
This study tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. The goal is to see if LTI-03 is safe and can protect lung cells, reduce scarring, and improve breathing compared to a placeb…
Phase: PHASE2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:01 UTC